MCMichael H. Cynamon

Michael H. Cynamon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael H. Cynamon has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Alex J. Chmielewski

    <!--label omitted: 1-->Department of Medicine, Veterans Affairs Medical Center, and Department of Medicine, State University of New York Health Science Center, Syracuse, New York

    1 shared publication
  • Anne M. J. A. Lenaerts

    <!--label omitted: 1-->Department of Medicine, Veterans Affairs Medical Center, and Department of Medicine, State University of New York Health Science Center, Syracuse, New York

    1 shared publication
  • C. A. Sharpe

    <!--label omitted: 1-->Veteran Affairs Medical Center and State University of New York Health Science Center, Syracuse, New York 13210

    1 shared publication
  • C. E. Swenson

    The Liposome Company Princeton, New Jersey 08540, USA

    1 shared publication
  • Carolyn M. Shoen

    State University of New York Upstate Medical University, Syracuse, NY, USA

    1 shared publication
  • John T. Welch

    <!--label omitted: 2-->Department of Chemistry, SUNY at Albany, Albany, New York 122222

    1 shared publication

Latest Publications

  • Open Access

    Durable Cure for Tuberculosis: Rifalazil in Combination with Isoniazid in a Murine Model of Mycobacterium tuberculosis Infection

    by Carolyn M. Shoen, Michelle S. DeStefano, Michael H. Cynamon

    Rifalazil (formerly known as KRM-1648) in combination with isoniazid has been found to be more active than rifampin/isoniazid. Administration of rifalazil/isoniazid for 12 weeks resulted in continued apparent sterilization of organs 6 months after cessation of therapy. In this study we evaluated the durability of rifalazil/isoniazid treatment. Female CD-1 mice were infected with Mycobacterium tuberculosis ATCC 35801 (strain Erdman). Rifalazil and isoniazid were given in combination for 6 and 12 weeks; no mycobacteria could be cultured from spleens and lungs at both the 6-week and 12-week time points. After completing treatment, groups of mice treated with rifalazil/isoniazid for 6 or 12 weeks were observed without any additional treatment. These observation groups were compared to groups of rifalazil/isoniazid-treated mice (6 and 12 weeks) given dexamethasone for 7 and 8 weeks, respectively. Modest regrowth was noted in the spleens and lungs of the group treated with rifalazil/isoniazid for 6 weeks. Regrowth in the 6-weeks group was enhanced slightly by treatment with dexamethasone. In contrast, no regrowth was noted in the 12-weeks rifalazil/isoniazid group, and treatment with dexamethasone did not result in any regrowth.


  • Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice

    by Anne M. J. A. Lenaerts, Sharon E. Chase, Alex J. Chmielewski, Michael H. Cynamon

    Besides direct bactericidal activity, long-term effectiveness is one of the most important features to consider when developing new drugs for chemotherapy. In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. The combination of RFP, isoniazid (INH), and pyrazinamide (PZA) administered daily resulted in an apparent clearance of M. tuberculosis organisms in the lungs and spleens of infected mice after 10 weeks of treatment. However, 3 months after the cessation of therapy, bacterial regrowth occurred in mice treated for a 12-week period, indicating a relapse of infection. In intermittent treatment regimens of RFP in combination with INH and PZA, sterilization was achieved when mice were treated two to five times per week for 9 weeks. Bacterial growth was still observed in the once-weekly treatment group. Our results show that mouse models can predict important parameters for new drugs. We stress the necessity for long-term posttreatment observation in animal models for the routine evaluation of new drugs for antituberculosis chemotherapy.


  • Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model

    by M. H. Cynamon, S. P. Klemens, C. A. Sharpe, S. Chase

    The activities of linezolid, eperezolid, and PNU-100480 were evaluated in a murine model of tuberculosis. Approximately 10 7 viable Mycobacterium tuberculosis ATCC 35801 organisms were given intravenously to 4-week-old outbred CD-1 mice. In the first study, treatment was started 1 day postinfection and was given by gavage for 4 weeks. Viable cell counts were determined from homogenates of spleens and lungs. PNU-100480 was as active as isoniazid. Linezolid was somewhat less active than PNU-100480 and isoniazid. Eperezolid had little activity in this model. In the next two studies, treatment was started 1 week postinfection. A dose-response study was performed with PNU-100480 and linezolid (both at 25, 50, and 100 mg/kg of body weight). PNU-100480 was more active than linezolid, and its efficacy increased with an escalation of the dose. Subsequently, the activity of PNU-100480 alone and in combination with rifampin or isoniazid was evaluated and was compared to that of isoniazid-rifampin. The activity of PNU-100480 was similar to that of isoniazid and/or rifampin in the various combinations tested. Further evaluation of these oxazolidinones in the murine test system would be useful prior to the development of clinical studies with humans.


  • In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide

    by Michael H. Cynamon, Robert J. Speirs, John T. Welch

    5-Chloropyrazinamide and 5-chloropyrazinoic acid were evaluated for in vitro activity against Mycobacterium tuberculosis , Mycobacterium bovis , and several nontuberculous mycobacteria by a broth dilution method. 5-Chloropyrazinamide was more active than pyrazinamide against all organisms tested. It is likely that this agent has a different mechanism of action than pyrazinamide.


  • TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice

    by M. H. Cynamon, S. Klemens, C. E. Swenson

    The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J—bg1/bg1) model of disseminated Mycobacterium avium infection. TLC G-65 was found to be more active than amikacin. The combination of rifapentine and TLC G-65 was more active than either agent alone. The activity of clarithromycin in combination with TLC G-65 was similar to that of either agent alone. Clofazimine improved the activity of TLC G-65 with respect to the spleen, while ethambutol improved the activity with respect to the liver. Clofazimine and ethambutol enhanced the activity of TLC G-65 against bacteria in the lungs. TLC G-65 in combination with rifapentine appears to be an attractive regimen for the treatment of infections caused by bacteria in the M. avium complex.


    • 1 September 1989
      • Vol. 10  (3) , 355-64

    New antimycobacterial agents.

    by M H Cynamon, S P Klemens

    Development of new antimycobacterial agents has gained impetus from the frequent occurrence of disseminated M. avium complex infections associated with the AIDS epidemic and the resurgence of tuberculosis. Promising new agents are being developed by modification of existing antimycobacterial agents (for example, aminoglycosides, macrolides, beta-lactams, and rifamycins) and by development of new therapeutic classes of drugs (for example, 4-quinolones). In addition, new drug delivery systems (liposome encapsulation) and immunomodulators may prove to be clinically useful in the treatment of some mycobacterial infections. New antimycobacterial agents will likely have their greatest impact on nontuberculous mycobacterial diseases because this is the area in which improved therapy is most needed. The specific role for new agents will be established only after more extensive study in animal models of mycobacterial infection is followed by controlled, randomized clinical trials.